Pfizer has asked the U.S. Food and Drug Administration to authorize its Covid-19 vaccine for children younger than five years old. It comes after trials showed a three-shot regimen was 80 percent effective. The Washington Post reports that Pfizer and its German partner, BioNTech, on Wednesday finished submitting an application for regulatory authorization of a coronavirus vaccine for children younger than 5. FDA advisers are scheduled to meet June 15 to discuss the three-shot Pfizer-BioNTech pediatric vaccine and a two-shot regimen from the biotechnology company Moderna. The agency is expected to act quickly, meaning young children could get their first shots this month.